Jonathan Rosenberg
Jonathan Rosenberg
Verified email at
Cited by
Cited by
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
S Mariathasan, SJ Turley, D Nickles, A Castiglioni, K Yuen, Y Wang, ...
Nature 554 (7693), 544-548, 2018
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm …
JE Rosenberg, J Hoffman-Censits, T Powles, MS Van Der Heijden, ...
The Lancet 387 (10031), 1909-1920, 2016
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
RM Samstein, CH Lee, AN Shoushtari, MD Hellmann, R Shen, ...
Nature genetics 51 (2), 202-206, 2019
Early childhood development coming of age: science through the life course
MM Black, SP Walker, LCH Fernald, CT Andersen, AM DiGirolamo, C Lu, ...
The Lancet 389 (10064), 77-90, 2017
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
AV Balar, MD Galsky, JE Rosenberg, T Powles, DP Petrylak, J Bellmunt, ...
The Lancet 389 (10064), 67-76, 2017
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, SS Ou, L Archer, ...
Journal of Clinical Oncology 26 (33), 5422, 2008
Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy
J Naidoo, X Wang, KM Woo, T Iyriboz, D Halpenny, J Cunningham, ...
Journal of Clinical Oncology 35 (7), 709, 2017
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206
BI Rini, S Halabi, JE Rosenberg, WM Stadler, DA Vaena, L Archer, ...
Journal of clinical oncology 28 (13), 2137, 2010
Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline
SS Chang, BH Bochner, R Chou, R Dreicer, AM Kamat, SP Lerner, ...
The Journal of urology 198 (3), 552-559, 2017
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
P Sharma, MK Callahan, P Bono, J Kim, P Spiliopoulou, E Calvo, ...
The lancet oncology 17 (11), 1590-1598, 2016
Enfortumab vedotin in previously treated advanced urothelial carcinoma
T Powles, JE Rosenberg, GP Sonpavde, Y Loriot, I Durán, JL Lee, ...
New England Journal of Medicine 384 (12), 1125-1135, 2021
Treatment of patients with metastatic urothelial cancer “unfit” for cisplatin-based chemotherapy
MD Galsky, NM Hahn, J Rosenberg, G Sonpavde, T Hutson, WK Oh, ...
Journal of Clinical Oncology 29 (17), 2432-2438, 2011
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
EM Van Allen, KW Mouw, P Kim, G Iyer, N Wagle, H Al-Ahmadie, C Zhu, ...
Cancer discovery 4 (10), 1140-1153, 2014
Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1/programmed death ligand 1 therapy
JE Rosenberg, PH O’Donnell, AV Balar, BA McGregor, EI Heath, EY Yu, ...
Journal of Clinical Oncology 37 (29), 2592-2600, 2019
Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior …
CJ Ryan, MR Smith, L Fong, JE Rosenberg, P Kantoff, F Raynaud, ...
Journal of clinical oncology 28 (9), 1481, 2010
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
BI Rini, MD Michaelson, JE Rosenberg, RM Bukowski, JA Sosman, ...
Journal of Clinical Oncology 26 (22), 3743-3748, 2008
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma
TK Choueiri, U Vaishampayan, JE Rosenberg, TF Logan, AL Harzstark, ...
Journal of Clinical Oncology 31 (2), 181, 2013
Alterations in DNA damage response and repair genes as potential marker of clinical benefit from PD-1/PD-L1 blockade in advanced urothelial cancers
MY Teo, K Seier, I Ostrovnaya, AM Regazzi, BE Kania, MM Moran, ...
Journal of Clinical Oncology 36 (17), 1685, 2018
Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
J Bellmunt, TK Choueiri, R Fougeray, FAB Schutz, Y Salhi, E Winquist, ...
Journal of Clinical Oncology 28 (11), 1850-1855, 2010
Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials
TK Choueiri, FAB Schutz, Y Je, JE Rosenberg, J Bellmunt
Journal of Clinical Oncology 28 (13), 2280-2285, 2010
The system can't perform the operation now. Try again later.
Articles 1–20